Category: Data


New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients

Dr. Shon Chakrabarti shares information on a recent publication from the Journal of Interventional Cardiology by Dr. Francesco Burzotta and colleagues on data from the Roma-Verona Registry. This study examined the long-term outcomes of complex high-risk patients with multivessel disease who were considered unsuitable for surgery and received an Impella-supported Protected PCI. Dr. Burzotta and … Continue reading “New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients”

New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery

New data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 sites demonstrates 72% survival with 98% native heart recovery at discharge. The patients were treated with the NCSI protocol, which includes placing the Impella heart pump before revascularization. The study demonstrates the protocol-based approach to … Continue reading “New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery”

Dr. Seth Bilazarian on the recent Circulation paper by Dr. Schrage/Dr. Ibrahim

Dr. Seth Bilazarian discusses a recent paper published in Circulation by Drs. Benedikt Schrage, Karim Ibrahim, et. al. on a retrospective matched-pair analysis comparing patients in cardiogenic shock treated with balloon pump and Impella. Dr. Bilazarian highlights several limitations of the analysis, which used a matched-pair analysis to “harmonize baseline characteristics” of Impella-treated patients with … Continue reading “Dr. Seth Bilazarian on the recent Circulation paper by Dr. Schrage/Dr. Ibrahim”

Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device

Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) database. The clinical publication highlights best practice protocols based on real-world evidence that is showing improved outcomes in cardiogenic shock. This clinical evidence is derived from Abiomed’s observational , commercial IQ database. In patients with AMICS receiving … Continue reading “Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device”

Use of Impella® Device to Assess Left Ventricular Function: A Proof-of-Concept Study

Left ventricular end-diastolic pressure (LVEDP) refers to the pressure in the LV at the end of diastolic filling and immediately before ventricular contraction.1 It is a useful measure to assess cardiac function and is typically inferred from pulmonary capillary wedge pressure (PCWP). However, PCWP is prone to significant errors and some studies report discordance of … Continue reading “Use of Impella® Device to Assess Left Ventricular Function: A Proof-of-Concept Study”

IMPRESS in Severe Shock Trial: Looking Closer at the Data

For patients with cardiogenic shock (CS), intra-aortic balloon pump (IABP) had been an important tool for maintaining patients and improving survival after percutaneous coronary intervention (PCI). Randomized controlled trials, however, have found very little evidence to support the notion that IABP is helpful for reducing mortality or improving hemodynamics for patients with CS.1,2 The Impella® … Continue reading “IMPRESS in Severe Shock Trial: Looking Closer at the Data”

Detroit Cardiogenic Shock Initiative: Initial Results

Data presented by Dr. William O’Neill of Henry Ford Hospital System at the 66th Annual Scientific Session of the American College of Cardiology also included new data from the Detroit Cardiogenic Shock Initiative (DCSI), an unprecedented collaboration between five heart hospitals in Detroit, with the goal of determining whether outcomes in cardiogenic shock can be … Continue reading “Detroit Cardiogenic Shock Initiative: Initial Results”

Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery

  Data from Abiomed’s Impella® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late-breaking Featured Clinical Research by Dr. William O’Neill of Henry Ford Hospital System at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, D.C. These data were derived from the IQ Database … Continue reading “Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery”

Detroit CSI: Collaboration to Improve Outcomes in Cardiogenic Shock

Announced Wednesday, the Detroit Cardiogenic Shock Initiative (CSI) is an innovative collaboration between five hospital systems in metro Detroit with the goal of determining whether outcomes in cardiogenic shock can be improved by using Impella® as early as possible for patients in the shock spiral. View the Full Story Here Led by Dr. Bill O’Neill … Continue reading “Detroit CSI: Collaboration to Improve Outcomes in Cardiogenic Shock”

Dr. William O’Neill: Impella for Cardiogenic Shock will be Major Advancement

In this Medpage Today video, Dr. William O’Neill of Detroit’s Henry Ford Hospital explains why Impella will be a major advancement for the treatment of cardiogenic shock. His prognosis is based in part on his performed registry which found the survival of over 60% in patients that were treated very early. Dr. O’Neill’s finding were … Continue reading “Dr. William O’Neill: Impella for Cardiogenic Shock will be Major Advancement”